JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 13 August 2007. doi:10.1136/jnnp.2007.118950
Journal of Neurology, Neurosurgery, and Psychiatry 2008;79:421-425
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnnp.2007.118950v1
79/4/421    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hill, M
Right arrow Articles by Ben-Shlomo, Y
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, M
Right arrow Articles by Ben-Shlomo, Y

RESEARCH PAPERS

Neurological care and risk of hospital mortality for patients with myasthenia gravis in England

M Hill1, Y Ben-Shlomo2

1 Institute of Clinical Neuroscience, University of Bristol, Bristol, UK
2 Department of Social Medicine, University of Bristol, Bristol, UK

Correspondence to:
Prof Yoav Ben-Shlomo, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Rd, Bristol B8 2PR, UK; y.ben-shlomo{at}bristol.ac.uk

Background: Myasthenia gravis (MG) is a rare neurological disorder, which can be life threatening. Although death is a rare outcome, evidence does not exist as to whether neurological care leads to any better outcome than care by other specialties.

Methods: A matched nested case control study sampled from all public sector hospital admissions in England with a primary diagnosis of MG from 1991 to 1999. Cases were defined as MG admissions which resulted in death and controls were other MG admissions, matched on sex, age (±2 years) and date of admission (±20 days) that were non-fatal. From a total of 18 251 finished consultant episodes with a mention of MG, we were able to create 196 matched sets with 196 fatal admissions and 788 control admissions.

Results: Admission under a neurologist was associated with a 69% reduced risk of death (OR 0.31, 95% CI 0.22 to 0.44; p<0.001). This was only slightly attenuated after adjustment for a variety of patient related and hospital covariates (OR 0.37, 95% CI 0.23 to 0.62; p<0.001).

Conclusions: This is the first evidence that patients admitted with MG are far less likely to die if they are under the care of a neurologist. We cannot determine whether this is because of better management per se or because neurologists are usually based in specialist centres and may have better intensive care support, or both. Alternatively, this may be a result of "selection bias" so that neurologists select less seriously ill patients.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.